Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD

Gastro-esophageal Reflux Disease Clinical Trial

— PEPTESTCN  

Official title:

Assessment of Equivalence of a Non-invasive In-vitro Diagnostic Test (Peptest) in Comparison to Other Routine Clinical Diagnostic Methods for GERD by Testing a Large Number of Clinical Samples

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02456779
• Other study ID #: PEPTESTCN
• Status: Completed
• Phase: N/A
• First received: May 21, 2015
• Last updated: December 7, 2017
• Start date: May 2015
• Est. completion date: November 2017

Study information

• Verified date: December 2017
• Source: MAAB (Shanghai) Medical Device Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of this clinical study is to determine whether Peptest (Human Pepsin lateral flow in vitro diagnostic medical device) is equivalent to other GERD diagnostic methods commonly applied in clinical practice by testing a large number of clinical samples.

This will be performed by evaluating Peptest results in GERD patients (Erosive esophagitis or NERD), defined using standard clinical procedures, and compared to healthy controls.

Description:

Gastroesophageal reflux disease (GERD) mainly manifests as three types, erosive esophagitis (EE), non-erosive reflux disease (NERD) and Barrett's esophagus. EE is characterized by damaged distal esophageal mucosa which is visible by endoscope, and also referred to as "endoscopically positive gastroesophageal reflux disease". NERD is defined as discomfort related to reflux without any obvious mucosal damage by endoscope, and is also known as "endoscopically negative gastroesophageal reflux disease".

At present the diagnosis of GERD uses syndrome-based diagnosis, proton pump inhibitor (PPI) test, 24-hour esophageal pH monitoring, endoscopy, etc. However, some of the above methods lack specificity and some may bring great suffering to patients due to being invasive (e.g., 24-hour esophagus pH monitoring). The disadvantage of endoscopy lies in its low detection rate, only 2.95% to 4.1% as NERD is the most frequent diagnosis. Therefore, diagnosis based on GERD syndromes still remains one of the most common diagnostic methods. In recent years, questionnaire surveys about GERD have been carried out at abroad, aiming at finding a simple and feasible diagnostic method. As one of the worlds's most recognized and commonly used diagnostic scale for the diagnosis of GERD, reflux disease questionnaire (RDQ) is a survey of medical history mainly based on symptom score. Studies at both home and abroad have confirmed its validity and reliability in the diagnosis of GERD. The reflux symptom index (RSI) is a validated questionnaire used to confirm the presence (or absence) of extra-esophageal reflux that are atypical symptoms of reflux that control subjects may overlook.

Peptest (Human Pepsin lateral flow in vitro diagnostic medical device) can be used in clinic for fast and convenient pepsin detection in patients' saliva. Pepsin, detected from saliva samples, can be regarded as a marker of a reflux event for the diagnosis of gastroesophageal reflux disease.

The primary objective of this study is to determine whether Peptest (Human Pepsin lateral flow in vitro diagnostic medical device) produced by RD Biomed Limited is equivalent to other GERD diagnostic methods commonly applied in clinical practice by testing a large number of clinical samples.

GERD patients and controls will provide saliva samples and these will be tested for the presence of pepsin using Peptest. Peptest results (positive or negative) will be evaluated in GERD patients (Erosive esophagitis or NERD) defined using standard clinical diagnostic tools and compared to controls (confirmed to not have reflux using two validated questionnaires).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1032
• Est. completion date: November 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Case group:

• Patients diagnosed as gastroesophageal reflux disease within 6 months had endoscopy within 6 months and presented with reflux symptoms in the past 4 weeks.

• Patients with RDQ questionnaire score of no less than 12 points.

• Patients who met the requirements and signed the informed consent.

• Collection and processing of samples should comply with the requirements of laboratory operation rules and product specifications.

Healthy group:

• Healthy subjects without any symptoms of gastroesophageal reflux, extra-esophageal reflux and laryngopharyngeal reflux.

• Healthy subjects with RDQ questionnaire score of 0.

• Healthy subjects with RSI questionnaire score of no more than 9 points and heartburn symptom score of 0.

• Healthy subjects who met the requirements and signed the informed consent.

• Collection and processing of samples should comply with the requirements of laboratory operation rules and product specifications.

Exclusion Criteria:

• Patients with functional heartburn.

• Patients who took gastric motor drugs within 7 days after entering the study.

• Patients with esophageal spasm and achalasia, eosinophilic esophagitis, dysphagia, esophageal or gastric cancer, and patients who received esophagus and stomach surgery

• Patients with serious hypohepatia or renal insufficiency

• Pregnant women

• Patients whose saliva samples were not appropriate for detection

• Samples not meeting the collection and processing requirements.

Related Conditions & MeSH terms

• Gastro-esophageal Reflux Disease
• Gastroesophageal Reflux

Intervention

Other:
• in vitro diagnostic test (Peptest)
saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
• Questionnaire
all recruited subjects to complete the RDQ as a determinant of inclusion criteria
• Questionnaire
control subjects to complete RSI as a determinant of inclusion criteria

Locations

Country	Name	City	State
China	Beijing Jishuitan Hospital	Beijing
China	Peking Union Medical College Hospital, Chinese Academy of Medical Sciences	Beijing
China	Huadong Hospital afflicted to Fudan University	Shanghai
China	Renji Hospital, School of Medicine, Shanghai Jiao Tong University	Shanghai
China	Ruijin Hospital, School of Medicine, Shanghai Jiaotong University,	Shanghai
China	Shanghai East Hospital Affiliated to Tongji University	Shanghai
China	The Shanghai Tenth People's Hospital of Tongji University	Shanghai
China	Tongji Hospital, Tongji University School of Medicine	Shanghai
China	Zhongshan Hospital, Fudan University	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
MAAB (Shanghai) Medical Device Limited	RD Biomed Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peptest result (+ or -)	Proportion of GERD patients Peptest positive compared to controls that are Peptest postitive	baseline
Secondary	Peptest result (+ or -)	Proportion of EE, NERD patients and control Peptest positive	baseline
Secondary	Peptest result (+ or -)	Proportion of GERD patients Peptest positive within 15 minutes of symptoms	baseline
Secondary	Peptest result (+ or -)	Proportion of Peptest positive in comparison to reference diagnostic test	baseline
Secondary	Safety (adverse events)	adverse events reported	baseline